Morgan Stanley analysts say a trial to test whether Novo Nordisk’s blockbuster weight-loss drug also will work against Alzheimer’s is likely to fail, as it set the most pessimistic target price forecast of any Wall Street bank on the Danish drugmaker.
Source link
Morgan Stanley expects Novo Nordisk Alzheimer trial to fail as it slashes rating
- Advertisement -